Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: irasia.com
$12.00
Provider: irasia.com
$23.00
Provider: irasia.com
$150.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CanTx Inc and Novogen Ltd appoints contract manufacturing organizations to produce clinical batches of the experimental anti cancer drug


Thursday, 24 Jul 2014 08:00pm EDT 

Novogen Ltd:Says that CanTx Inc, and its parent company, Novogen Ltd announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil.CanTx and Novogen expect to file an Investigational New Drug (IND) application for Cantrixil early next year and to advance this compound into the clinic by mid 2015.Cantrixil, being developed by CanTx Inc, a joint venture company between Novogen and Yale University, has been developed specifically to treat cancers wholly or largely confined to the abdomen.The potential of Cantrixil has emerged from studies at Yale that has developed screening tools to assess new drug candidates in the treatment of ovarian cancer. 

Company Quote

2.58
-0.15 -5.49%
19 Dec 2014